New Features information at Pharmaceutical Technology New and updated information from Features listed on www.pharmaceutical-technology.com http://www.pharmaceutical-technology.com/ en-us http://www.pharmaceutical-technology.com/ New Features information at Pharmaceutical Technology http://www.pharmaceutical-technology.com/content/images/logo_big.gif Ibuprofen: could this ubiquitous drug be entering a whole new era? http://www.pharmaceutical-technology.com/features/featureibuprofen-could-this-ubiquitous-drug-be-entering-a-whole-new-era-5688738/ http://www.pharmaceutical-technology.com/features/featureibuprofen-could-this-ubiquitous-drug-be-entering-a-whole-new-era-5688738/ Ibuprofen could soon be entering a new era, thanks to breakthrough research on the cardiovascular effects of one formulation of the drug. With one eye on the future, we look back at the medication’s more than 50 year history, to see how it’s become j… Thu, 08 Dec 2016 00:00:00 GMT November's top stories: Patheon to buy API facility, UK NICE approved Celgene’s drug http://www.pharmaceutical-technology.com/features/featurenovembers-top-stories-patheon-to-buy-api-facility-uk-nice-approves-celgenes-drug-5689815/ http://www.pharmaceutical-technology.com/features/featurenovembers-top-stories-patheon-to-buy-api-facility-uk-nice-approves-celgenes-drug-5689815/ Patheon agreed to acquire a new API manufacturing facility in the US, and UK NICE approved Celgene’s Imnovid drug for use in relapsed myeloma patients. Pharmaceutical-technology.com wraps up the key headlines from November. Wed, 07 Dec 2016 00:00:00 GMT Pfizer’s big antibiotic buyout: a sign of things to come? http://www.pharmaceutical-technology.com/features/featurepfizers-big-antibiotic-buyout-a-sign-of-things-to-come-5677454/ http://www.pharmaceutical-technology.com/features/featurepfizers-big-antibiotic-buyout-a-sign-of-things-to-come-5677454/ Pfizer’s acquisition of AstraZeneca’s antibiotics unit will certainly strengthen its anti-infectives portfolio, but is it also a precursor to bigger moves from the US drug maker? Elly Earls reports. Mon, 05 Dec 2016 00:00:00 GMT Ketamine: taking aim at depression http://www.pharmaceutical-technology.com/features/featureketamine-taking-aim-at-depression-5676318/ http://www.pharmaceutical-technology.com/features/featureketamine-taking-aim-at-depression-5676318/ Since the turn of the millennium, researchers have been investigating ketamine as a potential treatment for major depression. Today, with the largest trial to date underway and several ketamine-like drugs under development, we are moving closer to un… Thu, 01 Dec 2016 00:00:00 GMT Pharma Technology Focus – Issue 53 http://www.pharmaceutical-technology.com/features/featurepharma-technology-focus-issue-53-5672142/ http://www.pharmaceutical-technology.com/features/featurepharma-technology-focus-issue-53-5672142/ In this issue: Pfizer’s acquisition of AstraZeneca’s antibiotics unit, new ideas to tackle antimicrobial resistance, vaccines to look out for in 2017, targeting Tourette syndrome, using ketamine to treat depression, and more. Thu, 17 Nov 2016 16:41:00 GMT Bernie vs. Big Pharma http://www.pharmaceutical-technology.com/features/featurebernie-vs-big-pharma-5672068/ http://www.pharmaceutical-technology.com/features/featurebernie-vs-big-pharma-5672068/ Vermont Senator Bernie Sanders has continued to rail against pharmaceutical industry pricing since losing the Democratic nomination to Hillary Clinton. With Sanders’s presidential ambitions scuppered, should the pharma industry fear the fury of a pol… Thu, 17 Nov 2016 00:00:00 GMT October's top stories: GSK shingles vaccine, Pfizer’s Inflectra injection in US http://www.pharmaceutical-technology.com/features/featureoctobers-top-stories-gsk-shingles-vaccine-pfizers-inflectra-injection-in-us-5665530/ http://www.pharmaceutical-technology.com/features/featureoctobers-top-stories-gsk-shingles-vaccine-pfizers-inflectra-injection-in-us-5665530/ GSK submitted a biologics licence application to the FDA for its candidate shingles vaccine Shingrix, Pfizer announced its introduction of Inflectra (infliximab-dyyb) for injection in the US and Teva agreed to sell Actavis Generics assets and operati… Thu, 10 Nov 2016 00:00:00 GMT Antibiotic resistance: the race for the prize http://www.pharmaceutical-technology.com/features/featureantibiotic-resistance-the-race-for-the-prize-5662608/ http://www.pharmaceutical-technology.com/features/featureantibiotic-resistance-the-race-for-the-prize-5662608/ The Longitude Prize has set the standard for competitions looking for disruptive new ideas to tackle the growing antimicrobial resistance crisis. Nesta’s Longitude Prize lead Tamar Ghosh discusses the competition process, now approaching the end of i… Tue, 08 Nov 2016 00:00:00 GMT Open debate: is it ever justified to withhold clinical trial data? http://www.pharmaceutical-technology.com/features/featureopen-debate-is-it-ever-justified-to-withhold-clinical-trial-data-5027386/ http://www.pharmaceutical-technology.com/features/featureopen-debate-is-it-ever-justified-to-withhold-clinical-trial-data-5027386/ The debate over open access to clinical trial data is not a new one, and in August two editorials in the New England Journal of Medicine drew the battle lines once more. The big question: does it strengthen academic research, or lead investigators vu… Thu, 03 Nov 2016 00:00:00 GMT Developing new drugs for Tourette syndrome http://www.pharmaceutical-technology.com/features/featuredeveloping-new-drugs-for-tourette-syndrome-5649137/ http://www.pharmaceutical-technology.com/features/featuredeveloping-new-drugs-for-tourette-syndrome-5649137/ Tourette syndrome is a complex condition, and unscrambling the neurological factors behind the disorder has been a major factor for those working on treatments. But researchers are coming ever closer to understanding its puzzling etiology and are dev… Wed, 26 Oct 2016 16:29:00 GMT Plague, Flu and Zika: could 2017 bring vaccines for all three? http://www.pharmaceutical-technology.com/features/featureplague-flu-and-zika-could-2017-bring-vaccines-for-all-three-5646416/ http://www.pharmaceutical-technology.com/features/featureplague-flu-and-zika-could-2017-bring-vaccines-for-all-three-5646416/ The global health community has reinvigorated its search for vaccines against epidemics, pandemics and bioterrorist threats. Elly Earls profiles three of the most promising contenders. Mon, 24 Oct 2016 23:00:00 GMT Pharma Technology Focus – Issue 52 http://www.pharmaceutical-technology.com/features/featurepharma-technology-focus-issue-52-5038098/ http://www.pharmaceutical-technology.com/features/featurepharma-technology-focus-issue-52-5038098/ In this issue: A report calls for Oxford and Cambridge to work together in the biopharma sector, IBM’s new lab-on-a-chip technology, whether harnessing telomerase could trick the ageing process, how BERG is using AI to develop drugs, and more. Thu, 20 Oct 2016 11:43:00 GMT Could activating telomerase trick the ageing process? http://www.pharmaceutical-technology.com/features/featurecould-activating-telomerase-trick-the-ageing-process-5027378/ http://www.pharmaceutical-technology.com/features/featurecould-activating-telomerase-trick-the-ageing-process-5027378/ The enzyme telomerase, which reverses chromosome deterioration in cells, is strongly implicated in the ageing process. But could stimulating its production prevent ageing, or might the risks outweigh the benefits? Abi Millar finds out. Wed, 19 Oct 2016 23:00:00 GMT Bringing together Oxford and Cambridge’s biopharma clusters http://www.pharmaceutical-technology.com/features/featurebringing-together-oxford-and-cambridges-biopharma-clusters-5026979/ http://www.pharmaceutical-technology.com/features/featurebringing-together-oxford-and-cambridges-biopharma-clusters-5026979/ Taken together, Oxford and Cambridge play host to two of the world’s top universities, five world-renowned research institutes, the UK’s two largest pharma firms and over 600 biotech and medical technology companies. Given their shared opportunities … Mon, 17 Oct 2016 23:00:00 GMT Back to biology: how BERG is using artificial intelligence to tackle cancer http://www.pharmaceutical-technology.com/features/featureback-to-biology-how-berg-is-using-artificial-intelligence-to-tackle-cancer-5026285/ http://www.pharmaceutical-technology.com/features/featureback-to-biology-how-berg-is-using-artificial-intelligence-to-tackle-cancer-5026285/ Pharmaceutical start-up BERG is using artificial intelligence to drive its back-to-biology approach to fighting cancer. Co-founder, president and CEO Niven R. Narain talks about the start-up. Tue, 11 Oct 2016 23:00:00 GMT September's top stories: US researchers developed Epilepsy drugs, GE's €150 million biopharmaceutical campus investment http://www.pharmaceutical-technology.com/features/featureseptembers-top-stories-us-researchers-to-develop-epilepsy-drugs-ges-150m-biopharmaceutical-campus-5024829/ http://www.pharmaceutical-technology.com/features/featureseptembers-top-stories-us-researchers-to-develop-epilepsy-drugs-ges-150m-biopharmaceutical-campus-5024829/ Researchers at Columbia University Medical Centre (CUMC) identified how anti-epileptic drug Perampanel blocks AMPA receptors in the brain, and GE planned to invest €150 million in a new biopharmaceutical manufacturing campus at Ireland. Pharmaceutica… Thu, 06 Oct 2016 23:00:00 GMT IBM’s lab on a chip breakthrough seeks out cancers origin http://www.pharmaceutical-technology.com/features/featureibms-lab-on-a-chip-breakthrough-seeks-out-cancers-origin-5014330/ http://www.pharmaceutical-technology.com/features/featureibms-lab-on-a-chip-breakthrough-seeks-out-cancers-origin-5014330/ Doctors could detect cancer earlier than ever before thanks to new nanoscale technology developed by IBM. Elly Earls meets Joshua Smith, one of the researchers behind the innovation, to find out how. Mon, 03 Oct 2016 23:00:00 GMT Pharma Technology Focus – Issue 51 http://www.pharmaceutical-technology.com/features/featurepharma-technology-focus-issue-51-5012919/ http://www.pharmaceutical-technology.com/features/featurepharma-technology-focus-issue-51-5012919/ In this issue: Efficiency in Australia’s pharma industry, India’s move to biosimilars, painkillers that don’t rely on opioids, NHS England’s funding of HIV drug PrEP, whether stem cell transplants can be used to treat MS, and more. Thu, 22 Sep 2016 10:49:00 GMT US Precision Medicine Initiative gears up for a massive e-health drive http://www.pharmaceutical-technology.com/features/featureus-precision-medicine-initiative-gears-up-for-a-massive-e-health-drive-5001799/ http://www.pharmaceutical-technology.com/features/featureus-precision-medicine-initiative-gears-up-for-a-massive-e-health-drive-5001799/ Personalised medicine has long been an aim of advanced health systems, and the US is looking to move ever closer to this goal with the Precision Medicine Initiative Cohort Program, a massive e-health database storing detailed health data over many ye… Wed, 21 Sep 2016 23:00:00 GMT Going global: India’s big biosimilar move http://www.pharmaceutical-technology.com/features/featuregoing-global-indias-big-biosimilar-move-5001775/ http://www.pharmaceutical-technology.com/features/featuregoing-global-indias-big-biosimilar-move-5001775/ With biosimilar versions of effective but expensive biologic treatments set to unlock major opportunities around the world, does India’s pharma sector and regulatory system have what it takes to repeat its generics success with much more complex bios… Mon, 19 Sep 2016 23:00:00 GMT